Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The turner-Warwick lecturer scheme 2021

The Turner-Warwick lecturer scheme is named after the Royal College of Physician’s first female president, Professor Dame Margaret Turner-Warwick, and commemorates her life-time achievements through recognising the exceptional work of Royal College of Physician’s trainees in the UK. The scheme showcases trainees’ contributions to healthcare as well as their ability to communicate and reach across wide-ranging medical training specialties  and levels.  In early 2022, an overall national winner will be announced from the 14 regional winners, which include two from Oxford, Dr Jasmine Gan, NIHR Academic Clinical Fellow and Clinical Lecturer, Dr Rajna Golubic.

DR JASMINE GAN

Dr Jasmine Gan, NIHR ACF at OUCAGS,  has been selected as the Turner-Warwick Lecturer winner for the Oxford and Thames Valley region with her lecture ‘Poor outcomes in delirium: finds from an observational cohort of over 1,700 unselected acute medicine patients’.

DR GAN'S ACKNOWLEDGEMENTS

Dr Gan expresses her gratitude to Professor Sarah Pendlebury, Professor of Medicine and Old Age Neuroscience (Nuffield Department of Clinical Neurosciences, University of Oxford)  and to OUCAGS for opportunities and resources offered. 

Dr RAJNA GOLUBIC

Dr Rajna Golubic, NIHR CL at OUCAGS, has been selected as the Turner-Warwick Lecturer winner for the Eastern region with her lecture ‘Novel treatments to improve metabolic health in obesity and type 2 diabetes: the effects of cotadutide’.

ABOUT Dr RAJNA GOLUBIC's LECTURE

Dr Golubic's lecture presented the evolving landscape of the management of metabolic disorders associated with obesity and type 2 diabetes (T2D) using a novel promising drug cotadutide with a similar mechanism of action to naturally occurring hormones glucagon-like peptide 1 and glucagon. Cotadutide is in development for non-alcoholic fatty liver disease and kidney disease, which are metabolic complications of obesity and T2D. There is a major unmet need for therapies which improve metabolic health and achieve disease-modifying weight loss thus increasing the chance of additional improvements in glucose, cardiovascular risk and mortality and slowing or reversing the disease progression.

In collaboration with AstraZeneca, Dr Golubic and colleagues conducted a randomised controlled study on 19 obese volunteers with T2D over 10 visits to determine the mechanism by which cotadutide causes weight loss. They performed comprehensive assessments of energy balance (intake and expenditure) using state-of-the-art methods in our NIHR Cambridge Clinical Research Facility (room calorimetry, energy intake monitors). After 42 days of treatment, an average weight loss was 4.0% in cotadutide group and 1.4% in placebo group (p=0.011, primary outcome). Strikingly, energy intake was 41% lower compared to placebo (p=0.037) while energy expenditure was initially unchanged, but after 6 weeks decreased in cotadutide group (p<0.001). There was a marked improvement in glucose control and lipid profile in cotadutide group. No safety concerns were raised.

This mechanistic study has determined that cotadutide promotes weight loss predominantly through reduction in appetite and energy intake with preservation of energy expenditure in the early phases of treatment.

Dr GOLUBIC's ACKNOWLEDGEMENTS

Dr Golubic would like to acknowledge Dr Mark Evans, reader in diabetic medicine and PI (Institute of Metabolic Science Cambridge); Jane Kennet, study coordinator; NIHR Cambridge Clinical Research Facility team; and AstraZeneca (funder)

Similar stories

18 Oxford ACF jobs available for 2022 - applications open Friday October 1st 2021

Health Education England - Thames Valley (HEE-TV) in partnership with Oxford University and OUCAGS has 18 prestigious NIHR Academic Clinical Fellowships (ACFs) to offer as part of the NIHR Integrated Academic Training Pathway.

19 Oxford ACF jobs available for 2021 - applications opening Thursday Oct 1st

Health Education England - Thames Valley (HEE-TV) in partnership with Oxford University and OUCAGS has 19 prestigious NIHR Academic Clinical Fellowships (ACFs) to offer as part of the NIHR Integrated Academic Training Pathway.

21 Oxford ACF jobs available for 2020 - applications opening Monday Oct 7th

Health Education England - Thames Valley in partnership with Oxford University and OUCAGS has 21 prestigious NIHR Academic Clinical Fellowships (ACFs) to offer as part of the NIHR Integrated Academic Training Pathway.

ACF Posts Recruitment for 2019 - Oxford Deanery as part of Health Education Thames Valley

Oxford ACF posts for 2019: applications open 8th October.